Regeneron (REGN) Stock Forecast & Price Target

Compare

5,127 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Strong Buy

15 Buy

5 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$847.06

▲(12.77% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $847.06 with a high forecast of $1,057.00 and a low forecast of $660.00. The average price target represents a 12.77% change from the last price of $751.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"488":"$488","773":"$773","1058":"$1,058","630.5":"$630.5","915.5":"$915.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":847.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$847.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":660,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$660.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[488,630.5,773,915.5,1058],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,771.87,793.8030769230769,815.7361538461538,837.6692307692308,859.6023076923077,881.5353846153846,903.4684615384615,925.4015384615384,947.3346153846154,969.2676923076923,991.2007692307692,1013.1338461538462,1035.066923076923,{"y":1057,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,771.87,777.6538461538462,783.4376923076923,789.2215384615384,795.0053846153846,800.7892307692307,806.5730769230769,812.3569230769231,818.1407692307693,823.9246153846153,829.7084615384615,835.4923076923077,841.2761538461538,{"y":847.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,771.87,763.2646153846154,754.6592307692308,746.0538461538462,737.4484615384615,728.843076923077,720.2376923076923,711.6323076923077,703.0269230769231,694.4215384615385,685.8161538461538,677.2107692307693,668.6053846153847,{"y":660,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":708.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":669.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":695.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":614.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":587.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":489.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":533.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":557.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":577.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":599.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":750.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":771.87,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,057

Average Price Target$847.06

Lowest Price Target$660.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tyler Van Buren

TD Cowen

$800→$820

Buy

9.17%

Upside

Reiterated

01/29/26

TD Cowen Sticks to Its Buy Rating for Regeneron (REGN)

Geoff Meacham

Citi

$900

Buy

19.82%

Upside

Reiterated

01/27/26

Citi Remains a Buy on Regeneron (REGN)

Brian Abrahams

RBC Capital

$745

Hold

-0.82%

Downside

Reiterated

01/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (NASDAQ: PNTG), Regeneron (NASDAQ: REGN) and Warby Parker (NYSE: WRBY)

Tazeen Ahmad

Bank of America Securities

$860

Buy

14.49%

Upside

Reiterated

01/27/26

Analysts' Top Healthcare Picks: Guardant Health (GH), Regeneron (REGN)

John Newman

Canaccord Genuity

$1,057

Buy

40.72%

Upside

Reiterated

01/26/26

Regeneron: Dupixent-Led Growth, EYLEA Franchise Stabilization, and High-Value Pipeline Catalysts Underpin Buy Rating

William Pickering

Bernstein

$911→$916

Buy

21.95%

Upside

Assigned

01/23/26

Regeneron: Earnings Reacceleration, Eylea HD and Dupixent Upside Drive Raised $916 Target and Outperform Rating

Cory Kasimov

Evercore ISI

$750→$875

Buy

16.49%

Upside

Reiterated

01/22/26

Regeneron price target raised to $875 from $750 at Evercore ISIRegeneron price target raised to $875 from $750 at Evercore ISI

Nico Chen

DBS

$910

Buy

21.15%

Upside

Reiterated

01/22/26

Regeneron (REGN) Receives a Buy from DBS

Terence Flynn

Morgan Stanley

$768

Hold

2.25%

Upside

Reiterated

01/20/26

Regeneron Pharmaceuticals: Dupixent-Driven Growth Offset by Patent Uncertainty, Supporting a Hold Rating

Akash Tewari

Jefferies

$870→$885

Buy

17.82%

Upside

Reiterated

01/14/26

Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)

Louise Chen

Scotiabank

$770

Hold

2.51%

Upside

Reiterated

01/14/26

Regeneron (REGN) Receives a Hold from Scotiabank

David Risinger

Leerink Partners

Buy

―

Reiterated

01/13/26

Leerink Partners Remains a Buy on Regeneron (REGN)

Gregory Renza

Truist Financial

Buy

―

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Avita Medical (NASDAQ: RCEL), OrthoPediatrics (NASDAQ: KIDS) and Regeneron (NASDAQ: REGN)

Salveen Richter

Goldman Sachs

$807→$914

Buy

21.68%

Upside

Reiterated

01/09/26

Regeneron price target raised to $914 from $807 at Goldman SachsRegeneron price target raised to $914 from $807 at Goldman Sachs

Evan Seigerman

BMO Capital

$850

Buy

13.16%

Upside

Reiterated

12/11/25

Regeneron (REGN) Receives a Buy from BMO Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tyler Van Buren

TD Cowen

$800→$820

Buy

9.17%

Upside

Reiterated

01/29/26

TD Cowen Sticks to Its Buy Rating for Regeneron (REGN)

Geoff Meacham

Citi

$900

Buy

19.82%

Upside

Reiterated

01/27/26

Citi Remains a Buy on Regeneron (REGN)

Brian Abrahams

RBC Capital

$745

Hold

-0.82%

Downside

Reiterated

01/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (NASDAQ: PNTG), Regeneron (NASDAQ: REGN) and Warby Parker (NYSE: WRBY)

Tazeen Ahmad

Bank of America Securities

$860

Buy

14.49%

Upside

Reiterated

01/27/26

Analysts' Top Healthcare Picks: Guardant Health (GH), Regeneron (REGN)

John Newman

Canaccord Genuity

$1,057

Buy

40.72%

Upside

Reiterated

01/26/26

Regeneron: Dupixent-Led Growth, EYLEA Franchise Stabilization, and High-Value Pipeline Catalysts Underpin Buy Rating

William Pickering

Bernstein

$911→$916

Buy

21.95%

Upside

Assigned

01/23/26

Regeneron: Earnings Reacceleration, Eylea HD and Dupixent Upside Drive Raised $916 Target and Outperform Rating

Cory Kasimov

Evercore ISI

$750→$875

Buy

16.49%

Upside

Reiterated

01/22/26

Regeneron price target raised to $875 from $750 at Evercore ISIRegeneron price target raised to $875 from $750 at Evercore ISI

Nico Chen

DBS

$910

Buy

21.15%

Upside

Reiterated

01/22/26

Regeneron (REGN) Receives a Buy from DBS

Terence Flynn

Morgan Stanley

$768

Hold

2.25%

Upside

Reiterated

01/20/26

Regeneron Pharmaceuticals: Dupixent-Driven Growth Offset by Patent Uncertainty, Supporting a Hold Rating

Akash Tewari

Jefferies

$870→$885

Buy

17.82%

Upside

Reiterated

01/14/26

Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)

Louise Chen

Scotiabank

$770

Hold

2.51%

Upside

Reiterated

01/14/26

Regeneron (REGN) Receives a Hold from Scotiabank

David Risinger

Leerink Partners

Buy

―

Reiterated

01/13/26

Leerink Partners Remains a Buy on Regeneron (REGN)

Gregory Renza

Truist Financial

Buy

―

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Avita Medical (NASDAQ: RCEL), OrthoPediatrics (NASDAQ: KIDS) and Regeneron (NASDAQ: REGN)

Salveen Richter

Goldman Sachs

$807→$914

Buy

21.68%

Upside

Reiterated

01/09/26

Regeneron price target raised to $914 from $807 at Goldman SachsRegeneron price target raised to $914 from $807 at Goldman Sachs

Evan Seigerman

BMO Capital

$850

Buy

13.16%

Upside

Reiterated

12/11/25

Regeneron (REGN) Receives a Buy from BMO Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months

xxx

Success Rate

15/25 ratings generated profit

Average Return

+3.80%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +3.80% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

20/25 ratings generated profit

Average Return

+19.92%

reiterated a buy rating 17 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +19.92% per trade.

2 Years

xxx

Success Rate

20/25 ratings generated profit

Average Return

+21.10%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +21.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 37 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. REGN average Analyst price target in the past 3 months is 847.06.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $10.74 with a range of $8.38 to $13.78. The previous quarter’s EPS was $11.83. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.81B with a range of $3.65B to $4.11B. The previous quarter’s sales results were $3.75B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron’s 12-month average price target is 847.06.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron has 12.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron has a consensus rating of Strong Buy which is based on 15 buy ratings, 5 hold ratings and 0 sell ratings.

What is Regeneron’s price target?

The average price target for Regeneron is 847.06. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,057.00 ,the lowest forecast is $660.00. The average price target represents 12.77% Increase from the current price of $751.13.

What do analysts say about Regeneron?

Regeneron’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Detailed List of Analyst Forecasts